Pharmaceutical - Respiratory and Pulmonary, Germany

Filter

Popular Filters

IQWiG finds no added benefit for GSK’s Anoro Ellipta in COPD

21-10-2014

According to the findings of an early benefit assessment under the German Act on the Reform of the Market…

Anoro ElliptaGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationRespiratory and Pulmonary

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

01-10-2014

German family-owned pharma major Boehringer Ingelheim is investing more than 100 million euros ($127…

Boehringer IngelheimGermanyMarkets & MarketingPharmaceuticalProductionRespimatRespiratory and PulmonarySpiriva RespimatUK

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

09-09-2014

German family-owned drug major Boehringer Ingelheim has reported Phase III trial results showing that…

AsthmaBoehringer IngelheimGermanyMajorPharmaceuticalPulmonologyResearchRespiratory and Pulmonarytiotropium

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

Minor added benefit of Novartis’ Ultibro/Xoterna Breezhaler in COPD, says IQWiG

19-02-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

GermanyNorthern EuropeNovartisPharmaceuticalPricingRegulationRespiratory and PulmonaryUltibro BreezhalerXoterna Breezhaler

Back to top